Cargando…
TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
Immunotherapy, a chemotherapy-free process, has emerged as a promising therapeutic strategy to prolong the overall survival (OS) of patients with non-small-cell lung cancer (NSCLC). However, effective stratification factors for immunotherapy remain unclear. The purpose of this study was to discuss t...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485033/ https://www.ncbi.nlm.nih.gov/pubmed/34603310 http://dx.doi.org/10.3389/fimmu.2021.732125 |
_version_ | 1784577452664684544 |
---|---|
author | Lu, Jun Zhong, Runbo Lou, Yuqing Hu, Minjuan Yang, Zhengyu Wang, Yanan Chen, Ya Zou, Benkun Zhang, Wei Wang, Huimin Han, Baohui |
author_facet | Lu, Jun Zhong, Runbo Lou, Yuqing Hu, Minjuan Yang, Zhengyu Wang, Yanan Chen, Ya Zou, Benkun Zhang, Wei Wang, Huimin Han, Baohui |
author_sort | Lu, Jun |
collection | PubMed |
description | Immunotherapy, a chemotherapy-free process, has emerged as a promising therapeutic strategy to prolong the overall survival (OS) of patients with non-small-cell lung cancer (NSCLC). However, effective stratification factors for immunotherapy remain unclear. The purpose of this study was to discuss the potential stratification factors of NSCLC immunotherapy using immune checkpoint inhibitors (ICIs) by integrating genomic profiling and tumor lesion–type information. In this study, 344 patients with NSCLC, whose clinical and tissue (including metastatic and primary lesions) mutation information was available, were included. The potential gene mutation status for predicting the outcomes of immunotherapy was screened by comparing the difference in mutation frequency between responders and non-responders. Our results indicated that the potential predictors of immunotherapy were significantly different, especially between patients with TP53(+) (including metastatic and primary lesions) and TP53(−) (including metastatic and primary lesions). According to this classification, patients with NSCLC who suggested immunotherapy had a higher OS than those who did not (25 months vs. 7 months, P < 0.0001, hazard ratio = 0.39). Collectively, this study provides a new perspective for screening immunotherapy predictors in NSCLC, suggesting that the TP53 mutation status and source of biopsy tissue should be considered during the development of immunotherapy biomarkers. |
format | Online Article Text |
id | pubmed-8485033 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84850332021-10-02 TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer Lu, Jun Zhong, Runbo Lou, Yuqing Hu, Minjuan Yang, Zhengyu Wang, Yanan Chen, Ya Zou, Benkun Zhang, Wei Wang, Huimin Han, Baohui Front Immunol Immunology Immunotherapy, a chemotherapy-free process, has emerged as a promising therapeutic strategy to prolong the overall survival (OS) of patients with non-small-cell lung cancer (NSCLC). However, effective stratification factors for immunotherapy remain unclear. The purpose of this study was to discuss the potential stratification factors of NSCLC immunotherapy using immune checkpoint inhibitors (ICIs) by integrating genomic profiling and tumor lesion–type information. In this study, 344 patients with NSCLC, whose clinical and tissue (including metastatic and primary lesions) mutation information was available, were included. The potential gene mutation status for predicting the outcomes of immunotherapy was screened by comparing the difference in mutation frequency between responders and non-responders. Our results indicated that the potential predictors of immunotherapy were significantly different, especially between patients with TP53(+) (including metastatic and primary lesions) and TP53(−) (including metastatic and primary lesions). According to this classification, patients with NSCLC who suggested immunotherapy had a higher OS than those who did not (25 months vs. 7 months, P < 0.0001, hazard ratio = 0.39). Collectively, this study provides a new perspective for screening immunotherapy predictors in NSCLC, suggesting that the TP53 mutation status and source of biopsy tissue should be considered during the development of immunotherapy biomarkers. Frontiers Media S.A. 2021-09-17 /pmc/articles/PMC8485033/ /pubmed/34603310 http://dx.doi.org/10.3389/fimmu.2021.732125 Text en Copyright © 2021 Lu, Zhong, Lou, Hu, Yang, Wang, Chen, Zou, Zhang, Wang and Han https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Lu, Jun Zhong, Runbo Lou, Yuqing Hu, Minjuan Yang, Zhengyu Wang, Yanan Chen, Ya Zou, Benkun Zhang, Wei Wang, Huimin Han, Baohui TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer |
title | TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer |
title_full | TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer |
title_fullStr | TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer |
title_full_unstemmed | TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer |
title_short | TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer |
title_sort | tp53 mutation status and biopsy lesion type determine the immunotherapeutic stratification in non-small-cell lung cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485033/ https://www.ncbi.nlm.nih.gov/pubmed/34603310 http://dx.doi.org/10.3389/fimmu.2021.732125 |
work_keys_str_mv | AT lujun tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer AT zhongrunbo tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer AT louyuqing tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer AT huminjuan tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer AT yangzhengyu tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer AT wangyanan tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer AT chenya tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer AT zoubenkun tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer AT zhangwei tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer AT wanghuimin tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer AT hanbaohui tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer |